Published in Medical Letter on the CDC and FDA, May 6th, 2007
"The premarket notification of the NanoChip(R) system and the Cystic Fibrosis assay to the FDA is an important milestone for Nanogen," said Howard C. Birndorf, Nanogen's chairman and CEO. "This submission not only meets the commitment we made to the FDA, but also receiving 510(K) clearance...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA